Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension J C PETRIE, T A JEFFERS, 0 J ROBB, A K SCOTT, J WEBSTER Summary and conclusions The effect of once-daily atenolol, sustained-release oxprenolol (a new formulation of oxprenolol presented as a compressed tablet in a waxed matrix), and longacting propranolol (a new formulation presented as spheroids in a capsule) was studied in a double-blind crossover trial in 23 carefully selected hypertensive outpatients. After a run-in period with matching placebo each patient received atenolol (100 mg/day), sustainedrelease oxprenolol (160 mg/day), long-acting propranolol (160 mg/day), and placebo according to a randomised sequence.
After four weeks' treatment with sustained-release oxprenolol blood pressure in the two to four hours before the next dose was not significantly lower than after placebo. The effectiveness of atenolol and of the new formulation of propranolol in reducing blood pressure was confirmed.
These results suggest that the present formulation of sustained-release oxprenolol should be reconsidered.
Introduction
We have compared conventional fixed doses of three betaadrenoceptor antagonists that are claimed to be suitable for once-daily use in hypertension-namely, atenolol, sustainedrelease oxprenolol (a compressed tablet in a waxed matrix), and long-acting propranolol (a spheroid formulation).
Patients and methods
Our procedure for selecting patients with mild hypertension has been described.' 2 Patients were excluded if their lying diastolic pressure fell below 90 mm Hg after a four-week outpatient run-in period with placebo. Suitable patients were then allocated in a randomised order to four treatment periods (double-blind, within-patient) of four weeks each.
Twenty-three patients were studied (12 men; average age 40 9 years, range 21-59). The drugs were taken once daily at 1800, the doses (atenolol 100 mg, sustained-release oxprenolol 160 mg, longacting propranolol 160 mg, or matching placebo) being considered to be approximately equivalent in effect.
Blood pressures were recorded with Hawksley random-zero sphygmomanometers (diastolic pressure phase 4) under standard conditions.' 2 The means of two blood-pressure readings and heart rates were recorded after five minutes' lying and two minutes' standing. A single measurement of heart rate and blood pressure was taken immediately after a two-step exercise test designed to produce a target untreated heart rate of 140/min.' 2 Measurements were made between 1400 and 1630 (20-22 hours after dosing), at the same time of day on each occasion for each patient. Patients were seen fortnightly. A questionnaire on symptoms was completed by a different observer from the one recording blood pressure.' 2 Compliance with drug taking, assessed by tablet counts, was satisfactory throughout ( > 90%).
Data on blood pressure, heart rate, and weight were analysed separately by analysis of variance after two and four weeks with each treatment. If the overall comparison between treatments, as assessed by the F test, was significant at the 5% level then pairs of adjusted means were compared using a t test. The standard deviation used in the t test was based on the residual mean square from the analysis of variance.
Results Table I lists the mean blood pressures, pulse rates, and weights during the run-in and treatment periods, and table II the levels of statistical significance.
After four weeks' treatment systolic and diastolic blood pressures measured lying, standing, and after exercise were significantly lower after atenolol and long-acting propranolol than after placebo, but the same was not true for sustained-release oxprenolol. Atenolol was significantly superior to sustained-release oxprenolol after four weeks' treatment in lowering systolic and diastolic blood pressures and heart rates in each position. Long-acting propranolol was also superior to sustained-release oxprenolol after four weeks, except for the effect on lying heart rates. There were no significant differences between atenolol and long-acting propranolol for the above measurements. Fourteen patients (61 %) achieved a supine diastolic blood pressure of 90 mm Hg or less after four weeks' treatment with atenolol and longacting propranolol compared with seven patients (30%) after treatment with sustained-release oxprenolol. All treatments were well tolerated.
Discussion
Four weeks' treatment with sustained-release oxprenolol taken once daily does not produce satisfactory control of blood pressure in the two to four hours before the next dose is due. Our findings confirm the small loss of control of blood pressure that occurs towards the end of the 24 hours when the next dose is due,3 and the return to control values of exercise systolic blood pressure responses 24 hours after sustained-release oxprenolol noted in volunteers.4 Contrasting evidence from two smaller studies (six patients in each; some patients also taking diuretics) does not seriously challenge our findings. In the first of these the reduction in blood pressure compared with the placebo reading 24 hours after dosing was only 7/4 mm Hg, readings during treatment with placebo were below 140/90 mm Hg, there were no exercise measurements, and there was no run-in period with placebo.5 The second study was carried out on patients already controlled with sustained-release oxprenolol and conducted during 3-24 hours after dosing.6 During this interval there was a progressive rise in post-exercise heart rate (from 87 to 102 beats/min) and an increase in blood pressure that did not reach statistical significance: standing blood pressure rose by 12/10 to 140/105 mm Hg. We reported continued reduction of blood pressure and exercise-induced tachycardia for at least 48 hours after withdrawing long-term atenolol.7
If the observations in our carefully controlled study are confirmed we conclude that the release characteristics of this formulation of sustained-release oxprenolol should be reconsidered. Our findings confirm the effectiveness of atenolol (100 mg once daily) and the long-acting propranolol formulation (160 mg once daily) and show them to be superior to sustainedrelease oxprenolol (160 mg once daily) in lowering blood pressure over 24 hours.
